Edwards Lifesciences (NYSE: EW) — Structural Heart Leader Showing Strong Growth and Technical Momentum
Edwards Lifesciences (NYSE: EW) trades around $87 and appears to be benefiting from a combination of improving fundamentals and a stock chart that is beginning to confirm the story.
The company is one of the leading names in structural heart disease treatment, with roots that stretch back to the first commercially available artificial heart valve. Today, Edwards has helped treat more than two million cardiac patients worldwide and has grown into a company valued at roughly $46 billion.
What stands out today is the company’s accelerating growth profile.
Edwards develops and sells therapies for patients with heart valve conditions, and management continues to benefit from earlier disease detection that is expanding the company’s addressable market. Its newest heart-related therapies segment was particularly impressive in the first quarter of 2026, delivering approximately 42% year-over-year growth.
The strong performance carried through to the company’s outlook.
Following a better-than-expected first-quarter earnings report, Edwards raised its full-year 2026 guidance and now expects constant-currency sales growth of 9% to 11%, representing projected revenue of $6.5 billion to $6.9 billion. Adjusted earnings per share guidance was also increased to a range of $2.95 to $3.05. Management expects operating margins to finish at the high end of its 28% to 29% target range, representing roughly 150 basis points of expansion.
The longer-term outlook remains attractive as well.
Management reiterated its target of roughly 10% average annual sales growth beginning in 2027 and beyond, along with annual operating margin expansion of 50 to 100 basis points. That’s the type of steady growth and profitability improvement that long-term investors like to see.
The technical picture is becoming increasingly supportive.
After spending roughly six months building a base between $75 and $87, the stock finally pushed through resistance near $87. According to the analysis provided, the breakout has already been tested successfully, with shares pulling back toward the $81 area before finding support and moving back toward the highs. With little overhead resistance remaining, the setup suggests buyers may still be in control.
Momentum indicators also remain healthy. The stock’s RSI recently registered 63, showing strength without reaching overbought levels, while higher RSI readings since February suggest buyers have become increasingly aggressive on each advance.
For investors looking for a company with growing exposure to structural heart therapies, rising margins, double-digit growth potential in key business segments, and a chart that appears to be breaking into a new phase of strength, Edwards Lifesciences is a name worth watching closely.
